retifanlimab   Click here for help

GtoPdb Ligand ID: 11583

Synonyms: hPD-1 mAb 7(1.2) [6] | INCMGA0012 | MGA012 | retifanlimab-dlwr | Zynyz®
Approved drug Immunopharmacology Ligand
retifanlimab is an approved drug (FDA (2023), EMA (2024))
Compound class: Antibody
Comment: Retifanlimab (MGA012) is a humanized IgG4 anti-PD-1 monoclonal antibody. It was developed by MacroGenics for anti-cancer potential. Retifanlimab blocks the interaction between PD-1 and its ligands PD-L1/2, and it acts as an immune checkpoint modulator.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
Classification Click here for help
Compound class Antibody
Ligand families/groups Immune checkpoint modulators
Approved drug? Yes (FDA (2023), EMA (2024))
International Nonproprietary Names Click here for help
INN number INN
11095 retifanlimab
Synonyms Click here for help
hPD-1 mAb 7(1.2) [6] | INCMGA0012 | MGA012 | retifanlimab-dlwr | Zynyz®
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 968
Other databases
GtoPdb PubChem SID 442878617
Search PubMed clinical trials retifanlimab
Search PubMed titles retifanlimab
Search PubMed titles/abstracts retifanlimab